{"analyses":[{"ciPctValue":"95","groupDescription":"With 176 evaluable participants per treatment arm, there would have been \\>=80% power to detect a difference across two treatment arms of 15% in the true percentage of patients that need transfusion was at least 30% in the superior group, with a 2.5% type I error rate.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7250","statisticalMethod":"Fisher Exact","testedNonInferiority":false},{"ciPctValue":"95","groupDescription":"With 176 evaluable participants per treatment arm, there would have been \\>=80% power to detect a difference across two treatment arms of 15% in the true percentage of patients that need transfusion was at least 30% in the superior group, with a 2.5% type I error rate.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8700","statisticalMethod":"Fisher Exact","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"141"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"163"}],"units":"Participants"}],"groups":[{"description":"Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG000","title":"DA + IV Iron"},{"description":"Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG001","title":"DA + Oral Iron"},{"description":"Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG002","title":"DA + Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Week 1 to Week 16","title":"Incidence of Patients Receiving at Least One Red Blood Cell (RBC) Transfusions","type":"SECONDARY","unitOfMeasure":"Participants"}